Find out about our clinical trials process
Diseases and medicines can affect people differently depending on their race, ethnicity, sex or age. It’s therefore vital that we represent the real-world disease population in our clinical trials to advance our understanding of new vaccines and medicines, to create better health outcomes for the patients who rely on us.
Clinical trials are governed by strict regulation. Throughout each trial the proceedings are monitored by government authorities as well as GSK’s own Global Safety Board (GSB).
A clinical development plan usually consists in three phases. Occasionally a fourth phase might be necessary if:
- we think the medicine can be improved;
- we need to provide answers to questions from the regulatory authorities.
The first time a new treatment or vaccine is tested in humans, it will usually be given to a small group of healthy volunteers. However in some cases – such as when a new medicine is being tested as a treatment for a terminal illness like cancer - it may be tested on volunteers who have the condition.
The principle objectives in Phase I are to:
- make sure that the new medicine presents no major safety issues;
- clarify that it can reach the targeted body area, and remain there long enough to deliver its benefits or induce the expected response;
- gain preliminary evidence that it could offer therapeutic value, or prevent the disease or condition.
If Phase I is successful, approval will be sought for a trial involving a larger group of people. Phase II trials will usually (but not always) include patients who have the condition the potential medicine is targeting, and aim to establish:
- appropriate dosing levels;
- potential effectiveness in treating the condition;
- potential effectiveness in preventing the disease (if the volunteer does not already have it);
At this stage, the performance of the medicine may be compared against a group of patients receiving a placebo. A placebo is a treatment that looks the same as the potential new medicine, but has no active ingredients.
In this way a reference group is established against which the performance of the new medicine can be judged. It is important that neither the patients nor the researchers have any idea which volunteers receive which treatment. This is known as double blind placebo control, and ensures there can be no bias in the reporting of the results.
If the results from Phase II are encouraging, we will seek to start one or several Phase III trials. These will be much larger trials, often involving hundreds, possibly thousands of participants coming from a range of different countries.
The principle objectives in Phase III are to:
- demonstrate the safety and effectiveness of the new medicine or vaccine in the typical patient likely to use it;
- confirm effective dosing levels;
- identify side effects or reasons why the treatment should not be given to certain groups of patients (known as ‘contraindications’);
- build knowledge of the benefits of the medicine or vaccine and compare them with any risks;
- compare results against any currently achieved by existing treatments.
If a new medicine or vaccine completes Phase III with positive results, we may seek regulatory approval to make it available in a range of countries or regions.
In the case of a new medicine, regulators will determine how it should be used, and which patients should qualify for it, based on all the evidence from clinical and pre-clinical studies. This is known as a medicine’s indication.
Monitoring medicines after launch
Monitoring is overseen by our Global Safety Board (GSB), which is chaired by our Chief Medical Officer and made up of senior physicians and scientists, as well as by the health authorities who approved the launch of the product.
Part of its remit is to review the information on the safety of our products as reports come in from patients and prescribers on the use of the medicines.
All the Board's decisions are guided by the need to ensure that the benefits of our medicines and vaccines always outweigh any risks. We continue to monitor patients' responses to our medicines through reports and regulator reporting systems. We follow this information to understand fully a new medicine's effectiveness. We also look for any adverse effects that may only become apparent as more patients use a treatment.
Report adverse event
For Belgium
Please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use (BCPH) of the Federal Agency for Medicines and Health Products (FAMHP) by following the procedure described on the website http://www.fagg-afmps.be or to GlaxoSmithKline Pharmaceuticals s.a./n.v. at the number +32 (0)10 85 85 00.
For Luxembourg
Please rereport adverse events to Ministère de la Santé du Grand-Duché de Luxembourg (Division de la Pharmacie et des Médicaments at fax number +35 (0)2 24795615 or by post) or to Centre Régional de Pharmacovigilance de Lorraine (fax number +33 (0)3 83 32 33 44 or crpv@chu-nancy.fr) or to GlaxoSmithKline Pharmaceuticals s.a./n.v. at number +32 (0)10 85 85 00.
